CARLSBAD, Calif. — Thermo Fisher Scientific today announced the Ion GeneStudio S5 Series, a new line of bench top next-generation sequencing (NGS) instruments that provides unmatched flexibility and scalability enabled by five Ion S5 chips, including the new Ion 550 chip, to facilitate wide-ranging experiments on a single platform. The new series also provides low cost per sample […]

–Collaboration will be a new service offering for Berry Genomics and entry point for 10x Genomics into the NIPT Market in China– PLEASANTON, Calif. & BEIJING–10x Genomics, Inc., a company focused on accelerating genomic discovery, and Berry Genomics Co. Ltd (SZSE:000710), a company devoted to developing and offering genomic solutions for genetic diseases, today announced […]

— MGI’s BGISEQ-500RS Genetic Sequencer, Forthcoming MGISEQ Genetic Sequencers Compatible with 10x Genomics Solutions— PLEASANTON, Calif. & SHENZHEN, China–10x Genomics, Inc. and MGI, a subsidiary of BGI, today announced that the BGISEQ-500RS genetic sequencer has met the rigorous standards of the new 10x Genomics Compatible Program. MGI will also ensure that the MGISEQ series genetic […]

Highlights: • Focused R&D expansion providing core competencies in biosensor chemistries and  bioassay solutions targeting pharma/biopharma applications for near and long-term portfolio expansion • Broadens cell analysis portfolio with addition of complementary plate reader-based cellular assays • Accelerates expansion into pharma/biopharma discovery and in vitro toxicology screening applications SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced […]

Industry-Leading Sequencing Technology for Under $20K SAN DIEGO–Illumina, Inc. (NASDAQ: ILMN) announced today the launch of the iSeqTM 100 Sequencing System. The new, next-generation sequencing (NGS) system delivers exceptional data accuracy, at a low capital cost, making Illumina technology available to virtually any lab. The combination of the company’s proven sequencing by synthesis (SBS) chemistry, along with the complementary […]

Industry-leading amplicon solution facilitates targeted next-generation sequencing in multiple application areas CARLSBAD, Calif. & SAN DIEGO–Thermo Fisher Scientific and Illumina, Inc. (NASDAQ: ILMN) today announced they have signed a commercial agreement that enables Illumina to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing (NGS) platforms. The best-in-class amplicon technology is highly effective in capturing DNA and […]

Goal set to exceed $140 million of NGS-related sales in 2018, up from over $115 million in 2017 New Enterprise Genomics Services to offer gene panel customization capabilities to customers GeneReader NGS System plans include enhanced chemistry, more powerful gene panels    Hilden, Germany, and Germantown, Maryland, January 8, 2018 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt […]

Companies Target Review Aimed at Molecular Oncology and Hereditary Diseases SAN DIEGO–Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology. The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a […]

SEATTLE and TOKYO — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and Riken Genesis, a subsidiary of Sysmex Corporation (TOKYO, 6869), today announced that they have entered into a partnership to  introduce nCounter-based diagnostic assays in Japan. Under this agreement, NanoString and Riken Genesis will collaborate to register, obtain reimbursement and […]

Emeryville, Calif. – Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today that it has entered into a research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) focused on optimizing BLI’s proprietary BeaconTMOptofluidic platform with the goal of helping to accelerate Pfizer’s monoclonal antibody (mAb) […]